Preparation method of pla1 type n-3 polyunsaturated fatty acid phospholipid

A technology of unsaturated fatty acids and fatty acid phospholipids, which is applied in the field of preparation of PLA1 type n-3 polyunsaturated fatty acid phospholipids, can solve the problems that free fatty acids are not suitable for human body to take directly, reduce the service life of immobilized enzymes, and increase the production cost, etc. Achieve the effects of improving cardiovascular health requirements, reducing total lipid intake, and increasing productivity

CN106893747BActive Publication Date: 2021-03-05COFCO GROUP +2
4 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
Publication Date
2021-03-05

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention provides a method for preparing PLA1 type n-3 polyunsaturated fatty acid phospholipids and PLA1 type n-3 polyunsaturated fatty acid phospholipids prepared by the method of the invention. Compared with the effect in the prior art that the catalytic reaction at the PLA1 position is not more than 66% achieved by using commercial enzymes such as Lecitase Ultra, TL IM, and SP435, the method of the present invention greatly improves the production of PLA1-type functional phospholipids. Rate.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention belongs to the field of using biocatalysis to prepare lipids, and specifically relates to the preparation of PLA1 type n- 3 methods of polyunsaturated fatty acid phospholipids. Background technique

[0002] Polyunsaturated fatty acid (PUFA) refers to a class of fatty acids with not less than 18 carbon atoms and more than two double bonds; among them, the PUFA whose first double bond appears at the third position of the methyl end of the carbon chain is called n -3 polyunsaturated fatty acids. Typical examples of n-3 polyunsaturated fatty acids include docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA). A large number of pharmacological and animal experiments have proved that DHA is necessary for the normal development of the retina and the normal function of the nervous system. In the brain and retina, DHA accounts for about 20% and about 35% of the total fatty acids there, respectively, and exists mainly in the form of phospho...

Examples

Embodiment Construction

[0056] Hereinafter, the present invention will be explained in detail.

[0057] As used herein, the term "PLA1 type n-3 polyunsaturated fatty acid phospholipid" refers to a glycerophospholipid with n-3 polyunsaturated fatty acid inserted into the 1 position of glycerol group, including PLA1 type n-3 polyunsaturated fatty acid phosphatidic acid , PLA1 type n-3 polyunsaturated fatty acid phosphatidyl, PLA1 type n-3 polyunsaturated fatty acid phosphatidylcholine, PLA1 type n-3 polyunsaturated fatty acid phosphatidylethanolamine, PLA1 type n-3 polyunsaturated fatty acid phospholipid Acylglycerol, PLA1 type n-3 polyunsaturated fatty acid phosphatidylinositol, etc. This type of phospholipid can be hydrolyzed by PLA1-type phospholipases or PLA1-type lipases. The "PLA1 type n-3 polyunsaturated fatty acid phospholipid" is also referred to as PLA1 type functional phospholipid herein. It should be noted that the fatty acid residue at the 2-position of the PLA1 functional phosphoglycery...